PressDecember 1, 2023 Weight loss MEAI: Clearmind Medicine’s Novel Obesity Drug Showed Positive Results in a Pre-Clinical Trial
PressDecember 1, 2023 Cybin Inc. Reports Positive Topline Data from Phase 2 Study of CYB003 in Major Depressive Disorder with 79% of Patients in Remission after Two 12mg Doses
PressNovember 30, 2023 Braxia Scientific Reports Q2 2024 Financial Results and Provides Corporate Update
PressNovember 30, 2023 Algernon Pharmaceuticals Receives Notice of Intention to Grant from Chinese Patent Office for Repirinast to Treat NASH and NAFLD
PressNovember 30, 2023 Global CNS Therapeutics Strategic Report 2023: Market to Reach $199 Billion by 2030 – Developing Market to Drive the Market Momentum, Asia-Pacific to Exhibit Fastest Growth
PressNovember 30, 2023 Numinus Wellness Inc. Announces Fourth Quarter and Full Year Fiscal 2023 Results
PressNovember 30, 2023 Incannex Healthcare Announces Completion of its Redomiciliation to the United States
PressNovember 29, 2023 Enveric Biosciences Receives Notice of Allowance from USPTO for Development of Glycosylated Psilocybin Derivatives
PressNovember 29, 2023 Update Provided on GBB Drink Lab, Inc. Litigation and Safety Shot Previously known as Jupiter Wellness
PressNovember 29, 2023 Beckley Retreats Launches Signature Program for Personal Discovery and Transformation
PressNovember 29, 2023 Clearmind Medicine Announces Positive Results from its Weight Loss and Metabolic Disorder Program with its Proprietary Psychedelic- Based Treatment
PressNovember 29, 2023 Optimi Health Achieves Genetics Milestone and Completes Psilocybin Extract Validation and Stability Testing
PressNovember 28, 2023 Clearmind Medicine to Participate in Traditional vs. Novel Psychedelics Virtual Event with Leading Industry Figures
PressNovember 28, 2023 Filament Health Signs Non-Binding Term Sheet for Convertible Note in Connection with Planned Business Combination
PressNovember 28, 2023 Algernon Pharmaceuticals Announces LOI for the Acquisition of its Chronic Cough Research Program by U.S. Based Seyltx for USD $2M and a 20% Equity Position
PressNovember 21, 2023 Silo Pharma Enters into Exclusive License Agreement with Medspray Pharma BV for Intranasal Technology used in SPC-15 Treatment for PTSD
PressNovember 21, 2023 Revive Therapeutics Provides Update of Novel Bucillamine Formulation Development
PressNovember 20, 2023 Cybin to Host CYB003 Topline Depression Study Review and R&D Briefing on November 30, 2023, in New York City
